Publications

Martin Karpefors, Daniel Lindholm, Samvel B. Gasparyan (2022). The maraca plot: A novel visualization of hierarchical composite endpoints.

DOI

Pardeep S. Jhund, Toru Kondo, Jawad H. Butt, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, Muthiah Vaduganathan, Samvel B. Gasparyan, Olof Bengtsson, Daniel Lindholm, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, David DeMets, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Lars Køber, Carolyn S. P. Lam, Felipe A. Martinez, Marc S. Sabatine, Sanjiv J. Shah, Scott D. Solomon, John J. V. McMurray (2022). Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.

DOI

Samvel B. Gasparyan, Elaine K. Kowalewski, Gary G. Koch (2022). Comments on 'Sample size formula for a win ratio endpoint' by RX Yu and J. Ganju.

DOI

Samvel B. Gasparyan, Joan Buenconsejo, Elaine K. Kowalewski, Jan Oscarsson, Olof Bengtsson, Russell Esterline, Gary G. Koch, Otavio Berwanger, Mikhail N. Kosiborod (2022). Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial.

DOI

Hiddo J.L. Heerspink, Remo HM Furtado, Otavio Berwanger, Gary G. Koch, Felipe Martinez, Omar Mukhtar, Subodh Verma, Samvel B. Gasparyan, Joan Buenconsejo, Russell Esterline, Jan Oscarsson, Philip Ambery, Anna Maria Langkilde, Mikhail N. Kosiborod (2022). Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection.

DOI

Samvel B. Gasparyan, Elaine K. Kowalewski, Folke Folkvaljon, Olof Bengtsson, Joan Buenconsejo, John Adler, Gary G. Koch (2021). Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials.

DOI

Mikhail N. Kosiborod, Russell Esterline, Remo HM Furtado, Jan Oscarsson, Samvel B. Gasparyan, Gary G. Koch, Felipe Martinez, Omar Mukhtar, Subodh Verma, Vijay Chopra, Joan Buenconsejo, Anna Maria Langkilde, Philip Ambery, Fengming Tang, Kensey Gosch, Sheryl L Windsor, Emily E Akin, Ronaldo V P Soares, Diogo D F Moia, Matthew Aboudara, Conrado Roberto, Hoffmann Filho, Audes D M Feitosa, Alberto Fonseca, Vishnu Garla, Robert A Gordon, Ali Javaheri, Cristiano P Jaeger, Paulo E Leaes, Michael Nassif, Michael Pursley, Fabio Serra Silveira, Weimar Kunz Sebba Barroso, José Roberto, Lazcano Soto, Lilia Nigro Maia, Otavio Berwanger (2021). Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19).

DOI

Pardeep S. Jhund, Piotr Ponikowski, Kieran F. Docherty, Samvel B. Gasparyan, Michael Böhm, Chern-En Chiang, Akshay S. Desai, Jonathon Howlett, Masafumi Kitakaze, Mark C. Petrie, Subodh Verma, Olof Bengtsson, Anna Maria Langkilde, Mikaela Sjöstrand, Silvio E. Inzucchi, Lars Køber, Mikhail N. Kosiborod, Felipe A. Martinez, Marc S. Sabatine, Scott D. Solomon, John J.V. McMurray (2021). Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF.

DOI

Mikhail N. Kosiborod, Otavio Berwanger, Gary G. Koch, Felipe Martinez, Subodh Verma, Vijay Chopra, Ali Javaheri, Philip Ambery, Samvel B. Gasparyan, Joan Buenconsejo, David Sjöström, Anna Maria Langkilde, Jan Oscarsson, Russell Esterline (2020). Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study.

DOI

Samvel B. Gasparyan, Folke Folkvaljon, Olof Bengtsson, Joan Buenconsejo, Gary G. Koch (2020). Adjusted win ratio with stratification: Calculation methods and interpretation.

DOI

Samvel B. Gasparyan, Yury Kutoyants (2012). Publications related to the PhD thesis.

PDF